<DOC>
	<DOC>NCT00475800</DOC>
	<brief_summary>This 39-week, open label study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2360 study.</brief_summary>
	<brief_title>Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Have completed the core CCOX189A2360 study Males and females over the 18 years old Treatment in the extension study is not considered appropriate by the treating physician Noncompliance or major protocol violation of the core study Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>celecoxib</keyword>
	<keyword>Cox-2</keyword>
	<keyword>knee</keyword>
</DOC>